Placeholder Banner

Positive results for Logical Therapeutics’ LT-NS001 vs. Naproxen clinical study

October 28, 2009
Logical Therapeutics, Inc. announced positive results of a Phase I/II clinical trial evaluating the gastrointestinal (GI) safety of its investigational drug LT-NS001, the first of a new class of bio-activated prodrugs being developed for the chronic treatment of arthritic conditions.